368 related articles for article (PubMed ID: 28283537)
1. Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment.
Anastasilakis AD; Yavropoulou MP; Makras P; Sakellariou GT; Papadopoulou F; Gerou S; Papapoulos SE
Eur J Endocrinol; 2017 Jun; 176(6):677-683. PubMed ID: 28283537
[TBL] [Abstract][Full Text] [Related]
2. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study.
Zanchetta MB; Boailchuk J; Massari F; Silveira F; Bogado C; Zanchetta JR
Osteoporos Int; 2018 Jan; 29(1):41-47. PubMed ID: 28975362
[TBL] [Abstract][Full Text] [Related]
3. Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates.
Uebelhart B; Rizzoli R; Ferrari SL
Osteoporos Int; 2017 Sep; 28(9):2701-2705. PubMed ID: 28540505
[TBL] [Abstract][Full Text] [Related]
4. The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injection.
Makras P; Yavropoulou MP; Polyzos SA; Papapoulos SE; Georgakopoulou D; Papatheodorou A; Anastasilakis AD
Osteoporos Int; 2024 Feb; 35(2):365-370. PubMed ID: 37783758
[TBL] [Abstract][Full Text] [Related]
5. Serum Profile of microRNAs Linked to Bone Metabolism During Sequential Treatment for Postmenopausal Osteoporosis.
Yavropoulou MP; Anastasilakis AD; Makras P; Papatheodorou A; Rauner M; Hofbauer LC; Tsourdi E
J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32521543
[TBL] [Abstract][Full Text] [Related]
6. Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports.
Aubry-Rozier B; Gonzalez-Rodriguez E; Stoll D; Lamy O
Osteoporos Int; 2016 May; 27(5):1923-5. PubMed ID: 26510845
[TBL] [Abstract][Full Text] [Related]
7. The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab.
Capozzi A; Lello S; Pontecorvi A
Gynecol Endocrinol; 2014 Jun; 30(6):403-8. PubMed ID: 24592987
[TBL] [Abstract][Full Text] [Related]
8. Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports.
Lamy O; Fernández-Fernández E; Monjo-Henry I; Stoll D; Aubry-Rozier B; Benavent-Núñez D; Aguado P; Gonzalez-Rodriguez E
Osteoporos Int; 2019 May; 30(5):1111-1115. PubMed ID: 30613866
[TBL] [Abstract][Full Text] [Related]
9. Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses.
Cosman F; Huang S; McDermott M; Cummings SR
J Bone Miner Res; 2022 Nov; 37(11):2112-2120. PubMed ID: 36088628
[TBL] [Abstract][Full Text] [Related]
10. THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis.
Anastasilakis AD; Polyzos SA; Makras P
Eur J Endocrinol; 2018 Jul; 179(1):R31-R45. PubMed ID: 29691303
[TBL] [Abstract][Full Text] [Related]
11. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
Papapoulos S; Lippuner K; Roux C; Lin CJ; Kendler DL; Lewiecki EM; Brandi ML; Czerwiński E; Franek E; Lakatos P; Mautalen C; Minisola S; Reginster JY; Jensen S; Daizadeh NS; Wang A; Gavin M; Libanati C; Wagman RB; Bone HG
Osteoporos Int; 2015 Dec; 26(12):2773-83. PubMed ID: 26202488
[TBL] [Abstract][Full Text] [Related]
12. Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report.
Lamy O; Gonzalez-Rodriguez E; Stoll D; Hans D; Aubry-Rozier B
J Clin Endocrinol Metab; 2017 Feb; 102(2):354-358. PubMed ID: 27732330
[TBL] [Abstract][Full Text] [Related]
13. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
[TBL] [Abstract][Full Text] [Related]
14. Circulating miRNAs Respond to Denosumab Treatment After 2 Years in Postmenopausal Women With Osteoporosis-the MiDeTe study.
Messner Z; Carro Vázquez D; Haschka J; Grillari J; Resch H; Muschitz C; Pietschmann P; Zwerina J; Hackl M; Kocijan R
J Clin Endocrinol Metab; 2023 Apr; 108(5):1154-1165. PubMed ID: 36408612
[TBL] [Abstract][Full Text] [Related]
15. Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures.
Lehmann T; Aeberli D
Osteoporos Int; 2017 Oct; 28(10):3067-3068. PubMed ID: 28589418
[No Abstract] [Full Text] [Related]
16. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
McClung MR; Lippuner K; Brandi ML; Zanchetta JR; Bone HG; Chapurlat R; Hans D; Wang A; Zapalowski C; Libanati C
Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386
[TBL] [Abstract][Full Text] [Related]
17. Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial.
Anastasilakis AD; Papapoulos SE; Polyzos SA; Appelman-Dijkstra NM; Makras P
J Bone Miner Res; 2019 Dec; 34(12):2220-2228. PubMed ID: 31433518
[TBL] [Abstract][Full Text] [Related]
18. Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months.
Anastasilakis AD; Polyzos SA; Makras P; Gkiomisi A; Bisbinas I; Katsarou A; Filippaios A; Mantzoros CS
Osteoporos Int; 2014 May; 25(5):1633-42. PubMed ID: 24599275
[TBL] [Abstract][Full Text] [Related]
19. Rebound-associated vertebral fractures after discontinuation of denosumab for the treatment of maxillitis.
Niimi R; Kono T; Nishihara A; Hasegawa M; Kono T; Sudo A
Osteoporos Int; 2018 Mar; 29(3):769-772. PubMed ID: 29230512
[TBL] [Abstract][Full Text] [Related]
20. Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
Cummings SR; San Martin J; McClung MR; Siris ES; Eastell R; Reid IR; Delmas P; Zoog HB; Austin M; Wang A; Kutilek S; Adami S; Zanchetta J; Libanati C; Siddhanti S; Christiansen C;
N Engl J Med; 2009 Aug; 361(8):756-65. PubMed ID: 19671655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
